Skip to main content
Premium Trial:

Request an Annual Quote

AxyS Pharmaceuticals Gains US Patents on Two Genes Linked to Disease

Premium

SOUTH SAN FRANCISCO, Calif.--AxyS Pharmaceuticals here last month received US patents on two proprietary genes, TULP 1 and TULP 2, that have been linked to two disease states. The disease linkages and details of some of the properties of TULP 1 are being published in the current issue of Nature Genetics, according to John Walker, AxyS's chairman and CEO. He declined further comment on the patents pending publication of the article.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.